文献速递头颈外科咽喉与嗓音

HPV阳性口咽癌患者术后放化疗剂量与患者报告的吞咽结局:MINT与E3311研究

Patient-Reported Swallowing Outcomes in HPV+ Oropharyngeal Cancer by Postoperative Chemoradiation Dose in MINT and E3311.
PubMed 文献 · Otolaryngol Head Neck Surg · 2025-05-28

本研究回顾性分析了2014至2021年间多机构接受经口机器人手术及风险分层降低剂量术后辅助放化疗的HPV阳性口咽鳞癌患者,按放疗剂量分组比较基线与治疗后1年MDADI综合评分变化。结果显示42至60 Gy范围内不同剂量组间MDADI变化及临床意义下降率均无显著差异。

要点

  • 42至60 Gy范围内不同放疗剂量组间MDADI评分变化无显著差异(ANOVA P=.46)。
  • 临床意义下降率在42至49 Gy组为39%、50至59 Gy组为52%、60 Gy组为44%(卡方P=.42)。
  • 42至49 Gy组中联合或不联合顺铂的临床意义下降率相似(33% vs 42%,差异1%,95%CI -29%至47%)。

核心结论

  • 术后辅助放化疗后1年,MDADI评分自基线的变化在42至60 Gy放疗剂量范围内无差异。

研究设计与样本

  • 回顾性研究,多机构,2014至2021年,纳入156例接受经口机器人手术及降低剂量术后辅助放化疗的HPV阳性口咽鳞癌患者。

主要发现

  • 42至49 Gy组(n=28)MDADI平均变化-7.2(SD 10.6),50至59 Gy组(n=82)为-11.3(SD 17.2),60 Gy组(n=46)为-9.1(SD 15.1)(ANOVA P=.46)。
  • 临床意义下降率在42至49 Gy组为11/28(39%),50至59 Gy组为43/82(52%),60 Gy组为20/46(44%)(卡方P=.42)。
  • 42至49 Gy组中联合顺铂者临床意义下降率为3/9(33%),未联合顺铂者为8/19(42%),差异1%(95%CI -29%至47%)。
  • 各剂量组胃造瘘管率相似。

关键数值与推荐

  • MINT研究中等风险组接受42 Gy放疗联合一剂顺铂100 mg/m2,低风险组不接受顺铂。
  • E3311研究中等风险组随机接受50 Gy或60 Gy放疗。
  • 主要结局为MDADI综合评分自基线至治疗后1年的变化,临床意义下降定义为≥10分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate the effect of deintensified postoperative adjuvant (chemo)radiation therapy (POA(C)RT) on patient-reported dysphagia outcomes in patients with human papillomavirus (HPV+) oropharyngeal squamous cell carcinoma (OPSCC). STUDY DESIGN: Retrospective. SETTING: Multiple institutions, 2014 to 2021. METHODS: Patients with HPV+ OPSCC underwent transoral robotic surgery and reduced-dose POA(C)RT by pathologic risk stratification. The Minimalist Trial (MINT) participants received 42 Gy radiation therapy (RT) with one dose of cisplatin 100 mg/m2 (intermediate-risk arm) or no cisplatin (low-risk arm). The intermediate-risk E3311 participants were randomized to 50 or 60 Gy RT. Analysis was per-protocol by RT dose group. The primary outcome was change in MD Anderson Dysphagia Inventory (MDADI) composite score from baseline to 1-year posttreatment, with a clinically meaningful decline (CMD) of ≥10 points. RESULTS: In total, 156 included patients received POA(C)RT: n = 28 at 42 to 49 Gy (n = 19 no cisplatin, n = 9 cisplatin), n = 82 at 50 to 59, and n = 46 at 60 Gy. Mean (SD) change in MDADI was -7.2 (10.6) in the 42 to 49 Gy group, -11.3 (17.2) in the 50 to 59 group, and -9.1 (15.1) in the 60 Gy group (analysis of variance [ANOVA] P = .46). The rate of CMD was 11/28 (39%) in the 42 to 49 Gy group, 43/82 (52%) in the 50 to 59 group, and 20/46 (44%) in the 60 Gy group (chi-square P = .42). The rate of CMD was similar in those receiving 42 to 49 Gy with (3/9, 33%) and without cisplatin (8/19, 42%) (diff. 1%, 95% CI -29% to 47%). Gastrostomy tube rates were similar across dose groups. CONCLUSION: Changes in dysphagia-related quality-of-life (MDADI) from baseline to 1 year after POA(C)RT did not differ by radiation dose in the range of 42 to 60 Gy.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Tharakan T, Puram SV, Paniello RC, et al. Patient-Reported Swallowing Outcomes in HPV+ Oropharyngeal Cancer by Postoperative Chemoradiation Dose in MINT and E3311. Otolaryngol Head Neck Surg. 2025. PMID: 40432516. doi:10.1002/ohn.1261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。